| 000 | 01688 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250516093757.0 | ||
| 264 | 0 | _c20121218 | |
| 008 | 201212s 0 0 eng d | ||
| 022 | _a1476-5608 | ||
| 024 | 7 |
_a10.1038/pcan.2012.18 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aEgerdie, R B | |
| 245 | 0 | 0 |
_aResponder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. _h[electronic resource] |
| 260 |
_bProstate cancer and prostatic diseases _cSep 2012 |
||
| 300 |
_a308-12 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAndrogen Antagonists _xtherapeutic use |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xpharmacology |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Hormonal _xtherapeutic use |
| 650 | 0 | 4 |
_aBone Density _xdrug effects |
| 650 | 0 | 4 |
_aBone Density Conservation Agents _xpharmacology |
| 650 | 0 | 4 | _aDenosumab |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aProstatic Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aRANK Ligand _xantagonists & inhibitors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aSaad, F | |
| 700 | 1 | _aSmith, M R | |
| 700 | 1 | _aTammela, T L J | |
| 700 | 1 | _aHeracek, J | |
| 700 | 1 | _aSieber, P | |
| 700 | 1 | _aKe, C | |
| 700 | 1 | _aLeder, B | |
| 700 | 1 | _aDansey, R | |
| 700 | 1 | _aGoessl, C | |
| 773 | 0 |
_tProstate cancer and prostatic diseases _gvol. 15 _gno. 3 _gp. 308-12 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/pcan.2012.18 _zAvailable from publisher's website |
| 999 |
_c21817263 _d21817263 |
||